Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
BMC Pharmacol Toxicol ; 22(1): 50, 2021 09 20.
Artículo en Inglés | MEDLINE | ID: mdl-34544493

RESUMEN

BACKGROUND: In septic mice, supplementing parenteral nutrition with 150 mg/day 3-hydroxybutyrate-sodium-salt (3HB-Na) has previously shown to prevent muscle weakness without obvious toxicity. The main objective of this study was to identify the toxic threshold of 3HB-Na supplementation in septic mice, prior to translation of this promising intervention to human use. METHODS: In a centrally-catheterized, antibiotic-treated, fluid-resuscitated, parenterally fed mouse model of prolonged sepsis, we compared with placebo the effects of stepwise escalating doses starting from 150 mg/day 3HB-Na on illness severity and mortality (n = 103). For 5-day survivors, also the impact on ex-vivo-measured muscle force, blood electrolytes, and markers of vital organ inflammation/damage was documented. RESULTS: By doubling the reference dose of 150 mg/day to 300 mg/day 3HB-Na, illness severity scores doubled (p = 0.004) and mortality increased from 30.4 to 87.5 % (p = 0.002). De-escalating this dose to 225 mg still increased mortality (p ≤ 0.03) and reducing the dose to 180 mg/day still increased illness severity (p ≤ 0.04). Doses of 180 mg/day and higher caused more pronounced metabolic alkalosis and hypernatremia (p ≤ 0.04) and increased markers of kidney damage (p ≤ 0.05). Doses of 225 mg/day 3HB-Na and higher caused dehydration of brain and lungs (p ≤ 0.05) and increased markers of hippocampal neuronal damage and inflammation (p ≤ 0.02). Among survivors, 150 mg/day and 180 mg/day increased muscle force compared with placebo (p ≤ 0.05) up to healthy control levels (p ≥ 0.3). CONCLUSIONS: This study indicates that 150 mg/day 3HB-Na supplementation prevented sepsis-induced muscle weakness in mice. However, this dose appeared maximally effective though close to the toxic threshold, possibly in part explained by excessive Na+ intake with 3HB-Na. Although lower doses were not tested and thus might still hold therapeutic potential, the current results point towards a low toxic threshold for the clinical use of ketone salts in human critically ill patients. Whether 3HB-esters are equally effective and less toxic should be investigated.


Asunto(s)
Ácido 3-Hidroxibutírico/administración & dosificación , Suplementos Dietéticos , Debilidad Muscular/terapia , Sepsis/terapia , Ácido 3-Hidroxibutírico/efectos adversos , Equilibrio Ácido-Base , Aldosterona/sangre , Animales , Encéfalo/patología , Suplementos Dietéticos/efectos adversos , Relación Dosis-Respuesta a Droga , Infusiones Parenterales , Cetonas/metabolismo , Riñón/patología , Hígado/patología , Masculino , Dosis Máxima Tolerada , Ratones Endogámicos C57BL , Debilidad Muscular/etiología , Debilidad Muscular/patología , Sepsis/complicaciones , Sepsis/patología , Índice de Severidad de la Enfermedad
2.
Trials ; 20(1): 61, 2019 Jan 17.
Artículo en Inglés | MEDLINE | ID: mdl-30654835

RESUMEN

BACKGROUND: Currently available prophylactic migraine treatment options are limited and are associated with many, often intolerable, side-effects. Various lines of research suggest that abnormalities in energy metabolism are likely to be part of migraine pathophysiology. Previously, a ketogenic diet (KD) has been reported to lead to a drastic reduction in migraine frequency. An alternative method to a strict KD is inducing a mild nutritional ketosis (0.4-2 mmol/l) with exogenous ketogenic substances. The aim of this randomised, placebo-controlled, double-blind, crossover, single-centre trial is to demonstrate safety and superiority of beta-hydroxybutyrate (ßHB) in mineral salt form over placebo in migraine prevention. METHODS/DESIGN: Forty-five episodic migraineurs (5-14 migraine days/months), with or without aura, aged between 18 and 65 years, will be recruited at headache clinics in Switzerland, Germany and Austria and via Internet announcements. After a 4-week baseline period, patients will be randomly allocated to one of the two trial arms and receive either the ßHB mineral salt or placebo for 12 weeks. This will be followed by a 4-week wash-out period, a subsequent second baseline period and, finally, another 12-week intervention with the alternative treatment. Co-medication with triptans (10 days per months) or analgesics (14 days per months) is permitted. The primary outcome is the mean change from baseline in the number of migraine days (meeting International Classification of Headache Disorders version 3 criteria) during the last 4 weeks of intervention compared to placebo. Secondary endpoints include mean changes in headache days of any severity, acute migraine medication use, migraine intensity and migraine and headache-related disability. Exploratory outcomes are (in addition to routine laboratory analysis) genetic profiling and expression analysis, oxidative and nitrosative stress, as well as serum cytokine analysis, and blood ßHB and glucose analysis (pharmacokinetics). DISCUSSION: A crossover design was chosen as it greatly improves statistical power and participation rates, without increasing costs. To our knowledge this is the first RCT using ßHB salts worldwide. If proven effective and safe, ßHB might not only offer a new prophylactic treatment option for migraine patients, but might additionally pave the way for clinical trials assessing its use in related diseases. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03132233 . Registered on 27 April 2017.


Asunto(s)
Ácido 3-Hidroxibutírico/administración & dosificación , Encéfalo/efectos de los fármacos , Suplementos Dietéticos , Metabolismo Energético/efectos de los fármacos , Trastornos Migrañosos/prevención & control , Ácido 3-Hidroxibutírico/efectos adversos , Ácido 3-Hidroxibutírico/farmacocinética , Adolescente , Adulto , Anciano , Analgésicos/uso terapéutico , Biomarcadores/sangre , Encéfalo/metabolismo , Estudios Cruzados , Suplementos Dietéticos/efectos adversos , Evaluación de la Discapacidad , Método Doble Ciego , Femenino , Humanos , Masculino , Persona de Mediana Edad , Trastornos Migrañosos/sangre , Trastornos Migrañosos/diagnóstico , Dimensión del Dolor , Ensayos Clínicos Controlados Aleatorios como Asunto , Suiza , Factores de Tiempo , Resultado del Tratamiento , Adulto Joven
3.
JPEN J Parenter Enteral Nutr ; 28(2): 65-75, 2004.
Artículo en Inglés | MEDLINE | ID: mdl-15080599

RESUMEN

BACKGROUND: Combining the amino acids arginine and glutamine with the leucine metabolite beta-hydroxy-beta-methylbutyrate (HMB) has been shown to reverse lean tissue loss in cancer and acquired immunodeficiency syndrome (AIDS) patients. Although each of these nutrients has been shown to be safe, the safety of this mixture has not been reported. Three double-blind studies examined the safety of the combination of HMB, arginine and glutamine on blood chemistries, hematology, emotional profile, and adverse events. METHODS: Study 1 was conducted in healthy adult males (n = 34), study 2 was in HIV patients with AIDS-associated weight loss (n = 43), and study 3 was in cancer patients with wasting (n = 32). Volunteers were assigned to either a placebo or a mixture of 3 g HMB, 14 g arginine, and 14 g glutamine per day. RESULTS: Across the 3 studies, HMB, arginine, and glutamine supplementation was not associated with any adverse indicators of health. The only significant changes noted were positive indicators of health status. HMB, arginine, and glutamine supplementation was associated with an improvement in emotional profile (p = .05), a decreased feeling of weakness (p = .03), and increased red blood cells, hemoglobin, hematocrit, lymphocytes, and eosinophils (p < .05) when compared with placebo-supplemented subjects. Blood creatinine levels were not changed. However, blood urea nitrogen increased (p = .01) with HMB, arginine, and glutamine supplementation, which was possibly caused by the additional nitrogen consumed or to the fact that ureagenesis is influenced by arginine and glutamine supplementation. CONCLUSION: These results show that HMB, arginine, and glutamine can be safely used to treat muscle wasting associated with AIDS and cancer.


Asunto(s)
Ácido 3-Hidroxibutírico/uso terapéutico , Arginina/uso terapéutico , Caquexia/tratamiento farmacológico , Suplementos Dietéticos , Glutamina/uso terapéutico , Síndrome de Emaciación por VIH/tratamiento farmacológico , Neoplasias/tratamiento farmacológico , Ácido 3-Hidroxibutírico/administración & dosificación , Ácido 3-Hidroxibutírico/efectos adversos , Arginina/administración & dosificación , Arginina/efectos adversos , Análisis Químico de la Sangre , Nitrógeno de la Urea Sanguínea , Quimioterapia Combinada , Femenino , Glutamina/administración & dosificación , Glutamina/efectos adversos , Humanos , Masculino , Neoplasias/complicaciones , Ensayos Clínicos Controlados Aleatorios como Asunto , Seguridad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA